Dr. Kunimoto is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2152 S Vineyard
Ste 136
Mesa, AZ 85210Phone+1 602-858-3690
Education & Training
Sidney Kimmel Medical College at Thomas Jefferson University/Wills Eye HospitalResidency, Ophthalmology, 2001 - 2004
Massachusetts General HospitalInternship, Internal Medicine, 1999 - 2000
Harvard Medical SchoolClass of 1999
Certifications & Licensure
AZ State Medical License 2006 - 2026
HI State Medical License 2005 - 2026
CA State Medical License 2015 - 2025
PA State Medical License 2001 - 2006
DE State Medical License 2002 - 2002- American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- Fellow (FAAO) American Academy of Ophthalmology
Clinical Trials
- A 3-Month Clinical Trial to Assess the Safety and Efficacy of the OZURDEX® Intraocular Implant in Patients With Diabetes Mellitus Start of enrollment: 2012 Nov 01
- Telescope Exchange Study Start of enrollment: 2017 Mar 22
- The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy Start of enrollment: 2019 Nov 15
Publications & Presentations
PubMed
- 143 citationsSubretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration Treatments TrialsAlex S. Willoughby, Gui-Shuang Ying, Cynthia A. Toth, Maureen G. Maguire, Russell Burns
Ophthalmology. 2015-09-01 - 15 citationsEndophthalmitis after penetrating keratoplasty: Microbiologic spectrum and susceptibility of isolatesDerek Y. Kunimoto, William Tasman, Christopher J. Rapuano, F Recchia, Brandon G. Busbee
American Journal of Ophthalmology. 2004-02-01 - 98 citationsIn vitro susceptibility of bacterial keratitis pathogens to ciprofloxacin. Emerging resistance.Derek Y Kunimoto, Savitri Sharma, Prashant Garg, Gullapalli N Rao
Ophthalmology. 1999-01-01
Authored Content
- Efficacy and Safety of Abicipar in Neovascular Age‐Related Macular Degeneration: 52-Week Results of Phase 3 Randomized Controlled StudyApril 2020
Press Mentions
Aviceda Therapeutics Announces Formation of Executive TeamJanuary 11th, 2021
Telescope Implanted in Eye Helps Thousands of Arizonans SeeNovember 7th, 2015
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
